Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma (Nasdaq: RPRX) will present at two investor conferences in early December 2025: Citi 2025 Global Healthcare Conference on Tuesday, December 2 at 3:15 p.m. ET and Evercore 8th Annual Healthcare Conference on Wednesday, December 3 at 3:50 p.m. ET.
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) will present at two investor conferences in early December 2025: Citi 2025 Global Healthcare Conference on Tuesday, December 2 at 3:15 p.m. ET and Evercore 8th Annual Healthcare Conference on Wednesday, December 3 at 3:50 p.m. ET.
The company said webcasts of both presentations will be available on its Events page and archived for a minimum of 30 days, allowing investors to view the presentations after the live sessions.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RPRX
In the Nov 26 session, RPRX gained 0.76%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Citi conference time
- 3:15 p.m. ET
- Citi 2025 Global Healthcare Conference on Tuesday, December 2, 2025
- Evercore conference time
- 3:50 p.m. ET
- Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025
- Webcast archive period
- 30 days
- Minimum period Royalty Pharma will archive the conference webcasts
Historical Context
-
Announced $275M synthetic royalty funding tied to Denali’s tividenofusp alfa.
-
Planned Citi and Evercore conference presentations with archived investor webcasts.
-
Reported Q3 2025 growth and raised full‑year Portfolio Receipts guidance.
-
Acquired 1% AMVUTTRA royalty interest from Blackstone for $310M.
-
Declared Q4 2025 dividend of $0.22 per Class A ordinary share.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:
- Citi’s 2025 Global Healthcare Conference on Tuesday, December 2 at 3:15 p.m. ET
- Evercore’s 8th Annual Healthcare Conference on Wednesday, December 3 at 3:50 p.m. ET
The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, among others, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.